Can anything shut down the Gold rally?
Investing.com -- Amesite Inc. (NASDAQ:AMST) stock surged 100% after the AI-powered enterprise solutions developer reported 63% revenue growth for its NurseMagic™ platform following the launch of its census-based Enterprise subscription model.
The company announced that Enterprise sales have now surpassed B2C sales, reflecting increased demand from post-acute care providers seeking scalable technology designed to ensure full reimbursement rates. Amesite also unveiled a new AI-powered automated form-fill solution for required government forms.
Brandon Owens, VP of Sales at Amesite, noted the company’s shift from selling to individual employees to serving entire patient populations within healthcare systems. This expansion comes as the Centers for Medicare & Medicaid Services (CMS) prepares to mandate the Hospice Outcomes and Patient Evaluation (HOPE) assessment in October, which is expected to increase documentation requirements.
Amesite’s AI-powered HOPE automation solution, part of NurseMagic™ Enterprise, is designed to help organizations auto-populate complex forms, reduce administrative time, and ensure full reimbursements.
The company’s approach differs from traditional EMR vendors by focusing on helping post-acute care organizations handle regulatory requirements through AI-powered tools. According to Amesite, the post-acute care market is growing at a CAGR of 8%, outpacing the acute care market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.